Comparative Pharmacology
Head-to-head clinical analysis: MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE versus XANAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE versus XANAX.
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE vs XANAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization.
Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.
0.5-2 mg slow IV over 2 minutes, may repeat q2-3min; typical total dose 2.5-5 mg. IM: 0.07-0.08 mg/kg (usual 5 mg).
Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.8-2.5 hours in healthy adults. In critically ill patients or those with hepatic impairment, half-life may extend to 2-6 hours. Obesity may prolong half-life due to increased volume of distribution.
Terminal elimination half-life: 11.2 hours (range 6.3–26.9 hours). With repeated dosing, half-life may prolong slightly; clinical context: allows once-daily dosing for most patients.
Primarily renal elimination of hydroxylated metabolites (midazolam 1-hydroxymidazolam and 4-hydroxymidazolam) as glucuronide conjugates. Only 0.03% of unchanged drug is excreted renally. Fecal excretion accounts for <2%.
Renal: ~80% (mainly as glucuronide metabolites, <20% unchanged). Fecal: <7%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine